Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents

Randall J. Dumont, Hayan Dayoub, Jin Zhong Li, Aaron S. Dumont, David F Kallmes, Gerald R. Hankins, Gregory A. Helm, Edward C. Benzel, James T. Rutka, Regis W. Haid, Richard G. Fessler

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

OBJECTIVE: Ex vivo gene therapy with the use of human mesenchymal stem cells (hMSCs) and bone morphogenetic protein (BMP) genes provides a local supply of precursor cells and a supraphysiological dose of osteoinductive molecules that may promote bone formation in patients with inadequate hMSC populations because of age, osteoporosis, metastatic bone disease, iatrogenic depletion, or other metabolic derangements. This study was undertaken to evaluate the efficacy of ex vivo gene therapy with the use of hMSCs and the BMP-9 gene to promote spinal fusion in the rat. METHODS: Sixteen athymic nude rats were treated with hMSCs transduced with recombinant, replication-defective Type 5 adenovirus containing the cytomegalovirus promoter and either the BMP-9 (Ad-BMP-9) or the β-galactosidase (Ad-β-gal) gene. Ad-β-gal served as the control. Each animal received a percutaneous, paraspinal injection of 106 hMSCs transduced with 50 plaque-forming units/cell adenovirus in the lumbar region, with Ad-BMP-9 on the left and Ad-β-gal on the right. At 8 weeks postinjection, computed tomographic scans of the lumbosacral spine were obtained, and the lumbosacral spine specimens were examined histologically. RESULTS: Both computed tomographic studies and histological analysis clearly demonstrated large volumes of ectopic bone at the Ad-BMP-9-transduced hMSC injection sites, resulting in successful spinal fusion and no evidence of nerve root compression or local or systemic toxicity. The contralateral regions that were treated with Ad-β-gal-transduced hMSCs showed no evidence of osteogenesis. CONCLUSION: The results of this study suggest that hMSC and BMP-9 ex vivo gene therapy may be useful in inducing spinal fusion as well as other related procedures and certainly warrants further clinical development.

Original languageEnglish (US)
Pages (from-to)1239-1245
Number of pages7
JournalNeurosurgery
Volume51
Issue number5
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Growth Differentiation Factor 2
Spinal Fusion
Mesenchymal Stromal Cells
Genetic Therapy
Rodentia
Galactosidases
Nude Rats
Adenoviridae
Osteogenesis
Spine
Genes
Lumbosacral Region
Bone Morphogenetic Proteins
Injections
Radiculopathy
Bone Diseases
Cytomegalovirus
Osteoporosis

Keywords

  • Adenoviral vector
  • Bone morphogenetic protein-9
  • Ex vivo gene therapy
  • Human mesenchymal stem cells
  • Spinal fusion

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. / Dumont, Randall J.; Dayoub, Hayan; Li, Jin Zhong; Dumont, Aaron S.; Kallmes, David F; Hankins, Gerald R.; Helm, Gregory A.; Benzel, Edward C.; Rutka, James T.; Haid, Regis W.; Fessler, Richard G.

In: Neurosurgery, Vol. 51, No. 5, 01.11.2002, p. 1239-1245.

Research output: Contribution to journalArticle

Dumont, RJ, Dayoub, H, Li, JZ, Dumont, AS, Kallmes, DF, Hankins, GR, Helm, GA, Benzel, EC, Rutka, JT, Haid, RW & Fessler, RG 2002, 'Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents', Neurosurgery, vol. 51, no. 5, pp. 1239-1245. https://doi.org/10.1097/00006123-200211000-00020
Dumont, Randall J. ; Dayoub, Hayan ; Li, Jin Zhong ; Dumont, Aaron S. ; Kallmes, David F ; Hankins, Gerald R. ; Helm, Gregory A. ; Benzel, Edward C. ; Rutka, James T. ; Haid, Regis W. ; Fessler, Richard G. / Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. In: Neurosurgery. 2002 ; Vol. 51, No. 5. pp. 1239-1245.
@article{08a15d5ad99e42bdbf567a6bef60f70b,
title = "Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents",
abstract = "OBJECTIVE: Ex vivo gene therapy with the use of human mesenchymal stem cells (hMSCs) and bone morphogenetic protein (BMP) genes provides a local supply of precursor cells and a supraphysiological dose of osteoinductive molecules that may promote bone formation in patients with inadequate hMSC populations because of age, osteoporosis, metastatic bone disease, iatrogenic depletion, or other metabolic derangements. This study was undertaken to evaluate the efficacy of ex vivo gene therapy with the use of hMSCs and the BMP-9 gene to promote spinal fusion in the rat. METHODS: Sixteen athymic nude rats were treated with hMSCs transduced with recombinant, replication-defective Type 5 adenovirus containing the cytomegalovirus promoter and either the BMP-9 (Ad-BMP-9) or the β-galactosidase (Ad-β-gal) gene. Ad-β-gal served as the control. Each animal received a percutaneous, paraspinal injection of 106 hMSCs transduced with 50 plaque-forming units/cell adenovirus in the lumbar region, with Ad-BMP-9 on the left and Ad-β-gal on the right. At 8 weeks postinjection, computed tomographic scans of the lumbosacral spine were obtained, and the lumbosacral spine specimens were examined histologically. RESULTS: Both computed tomographic studies and histological analysis clearly demonstrated large volumes of ectopic bone at the Ad-BMP-9-transduced hMSC injection sites, resulting in successful spinal fusion and no evidence of nerve root compression or local or systemic toxicity. The contralateral regions that were treated with Ad-β-gal-transduced hMSCs showed no evidence of osteogenesis. CONCLUSION: The results of this study suggest that hMSC and BMP-9 ex vivo gene therapy may be useful in inducing spinal fusion as well as other related procedures and certainly warrants further clinical development.",
keywords = "Adenoviral vector, Bone morphogenetic protein-9, Ex vivo gene therapy, Human mesenchymal stem cells, Spinal fusion",
author = "Dumont, {Randall J.} and Hayan Dayoub and Li, {Jin Zhong} and Dumont, {Aaron S.} and Kallmes, {David F} and Hankins, {Gerald R.} and Helm, {Gregory A.} and Benzel, {Edward C.} and Rutka, {James T.} and Haid, {Regis W.} and Fessler, {Richard G.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1097/00006123-200211000-00020",
language = "English (US)",
volume = "51",
pages = "1239--1245",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents

AU - Dumont, Randall J.

AU - Dayoub, Hayan

AU - Li, Jin Zhong

AU - Dumont, Aaron S.

AU - Kallmes, David F

AU - Hankins, Gerald R.

AU - Helm, Gregory A.

AU - Benzel, Edward C.

AU - Rutka, James T.

AU - Haid, Regis W.

AU - Fessler, Richard G.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - OBJECTIVE: Ex vivo gene therapy with the use of human mesenchymal stem cells (hMSCs) and bone morphogenetic protein (BMP) genes provides a local supply of precursor cells and a supraphysiological dose of osteoinductive molecules that may promote bone formation in patients with inadequate hMSC populations because of age, osteoporosis, metastatic bone disease, iatrogenic depletion, or other metabolic derangements. This study was undertaken to evaluate the efficacy of ex vivo gene therapy with the use of hMSCs and the BMP-9 gene to promote spinal fusion in the rat. METHODS: Sixteen athymic nude rats were treated with hMSCs transduced with recombinant, replication-defective Type 5 adenovirus containing the cytomegalovirus promoter and either the BMP-9 (Ad-BMP-9) or the β-galactosidase (Ad-β-gal) gene. Ad-β-gal served as the control. Each animal received a percutaneous, paraspinal injection of 106 hMSCs transduced with 50 plaque-forming units/cell adenovirus in the lumbar region, with Ad-BMP-9 on the left and Ad-β-gal on the right. At 8 weeks postinjection, computed tomographic scans of the lumbosacral spine were obtained, and the lumbosacral spine specimens were examined histologically. RESULTS: Both computed tomographic studies and histological analysis clearly demonstrated large volumes of ectopic bone at the Ad-BMP-9-transduced hMSC injection sites, resulting in successful spinal fusion and no evidence of nerve root compression or local or systemic toxicity. The contralateral regions that were treated with Ad-β-gal-transduced hMSCs showed no evidence of osteogenesis. CONCLUSION: The results of this study suggest that hMSC and BMP-9 ex vivo gene therapy may be useful in inducing spinal fusion as well as other related procedures and certainly warrants further clinical development.

AB - OBJECTIVE: Ex vivo gene therapy with the use of human mesenchymal stem cells (hMSCs) and bone morphogenetic protein (BMP) genes provides a local supply of precursor cells and a supraphysiological dose of osteoinductive molecules that may promote bone formation in patients with inadequate hMSC populations because of age, osteoporosis, metastatic bone disease, iatrogenic depletion, or other metabolic derangements. This study was undertaken to evaluate the efficacy of ex vivo gene therapy with the use of hMSCs and the BMP-9 gene to promote spinal fusion in the rat. METHODS: Sixteen athymic nude rats were treated with hMSCs transduced with recombinant, replication-defective Type 5 adenovirus containing the cytomegalovirus promoter and either the BMP-9 (Ad-BMP-9) or the β-galactosidase (Ad-β-gal) gene. Ad-β-gal served as the control. Each animal received a percutaneous, paraspinal injection of 106 hMSCs transduced with 50 plaque-forming units/cell adenovirus in the lumbar region, with Ad-BMP-9 on the left and Ad-β-gal on the right. At 8 weeks postinjection, computed tomographic scans of the lumbosacral spine were obtained, and the lumbosacral spine specimens were examined histologically. RESULTS: Both computed tomographic studies and histological analysis clearly demonstrated large volumes of ectopic bone at the Ad-BMP-9-transduced hMSC injection sites, resulting in successful spinal fusion and no evidence of nerve root compression or local or systemic toxicity. The contralateral regions that were treated with Ad-β-gal-transduced hMSCs showed no evidence of osteogenesis. CONCLUSION: The results of this study suggest that hMSC and BMP-9 ex vivo gene therapy may be useful in inducing spinal fusion as well as other related procedures and certainly warrants further clinical development.

KW - Adenoviral vector

KW - Bone morphogenetic protein-9

KW - Ex vivo gene therapy

KW - Human mesenchymal stem cells

KW - Spinal fusion

UR - http://www.scopus.com/inward/record.url?scp=0036871171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036871171&partnerID=8YFLogxK

U2 - 10.1097/00006123-200211000-00020

DO - 10.1097/00006123-200211000-00020

M3 - Article

C2 - 12383369

AN - SCOPUS:0036871171

VL - 51

SP - 1239

EP - 1245

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 5

ER -